市場調查報告書
商品編碼
966336

後期慢性腎衰竭治療藥的全球市場:未來預測 (到2027年),各產品種類、各症狀、各流通管道、各地區的分析,新型冠狀病毒感染疾病 (COVID-19)的影響

Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type ; Indication ; Distribution Channel, and Geography

出版日期: | 出版商: The Insight Partners | 英文 194 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球後期慢性腎衰竭治療藥的市場規模,預計從2019年的46億8000萬,到2027年擴大到110億9690萬美元。還有2020∼2027年的年複合成長率估計為11.6%。

本報告提供全球後期慢性腎臟病治療藥的市場相關分析,市場基本結構和背景情況 (主要促進、阻礙因素等),市場規模趨勢預測 (今後9年份),各產品種類、各症狀、各流通管道、各地區的詳細趨勢,主要企業的簡介與策略展開情形,近來的新型冠狀病毒感染疾病 (COVID-19) 伴隨的影響等資訊彙整,為您概述為以下內容。

目錄

第1章 簡介

第2章 後期慢性腎衰竭治療藥市場:分析概要

第3章 分析方法

第4章 後期慢性腎衰竭治療藥市場:市場環境

  • 概要
  • PEST分析
  • 專家的見解

第5章 全球後期慢性腎衰竭治療藥市場:市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 今後趨勢
  • 推動及阻礙市場要素的影響度分析

第6章 後期慢性腎衰竭治療藥市場:全球市場分析

  • 市場收益額的預測與分析
  • 市場規模的預測與分析:各地區
  • 主要企業的市場定位

第7章 後期慢性腎衰竭治療藥市場:各產品種類分析

  • 概要
  • 後期慢性腎衰竭治療藥市場:各產品種類佔有率 (2019年,2027年)
  • 鈣受體激動劑 (擬鈣劑)
  • 維他命D
  • 鉀粘合劑 (黏合劑)
  • 鈣為基礎的磷吸附劑
  • 其他

第8章 後期慢性腎衰竭治療藥市場:各適應症分析

  • 概要
  • 後期慢性腎衰竭治療藥市場:各適應症佔有率 (2019年,2027年)
  • 後期慢性腎衰竭誘發性副甲狀腺機能亢進症
  • 後期慢性腎衰竭誘發性高磷酸鹽血症
  • 後期慢性腎衰竭誘發性量鉀血症

第9章 後期慢性腎衰竭治療藥市場:各流通管道分析

  • 概要
  • 後期慢性腎衰竭治療藥市場:各流通管道佔有率 (2019年,2027年)
  • 醫院藥局
  • 線上藥局
  • 零售藥局

第10章 後期慢性腎衰竭治療藥市場分析、預測:各地區的分析

  • 北美:後期慢性腎衰竭治療藥的市場
  • 歐洲:後期慢性腎衰竭治療藥的市場
  • 亞太地區:後期慢性腎衰竭治療藥的市場
  • 中東、非洲:後期慢性腎衰竭治療藥的市場
  • 中南美:後期慢性腎衰竭治療藥的市場

第11章 COVID-19感染擴大對全球後期慢性腎衰竭治療藥市場的影響

  • 北美:COVID-19感染擴大的影響度的評估
  • 歐洲:COVID-19感染擴大的影響度的評估
  • 亞太地區:COVID-19感染擴大的影響度的評估
  • 其他國家 (RoW):COVID-19感染擴大的影響度的評估

第12章 後期慢性腎衰竭治療藥的市場:產業形勢

  • 概要
  • 各企業展開的成長策略
  • 有機的發展
  • 無機的發展

第13章 企業簡介

  • AbbVie Inc.
  • Amgen
  • AstraZeneca
  • Sanofi
  • Kyowa Kirin Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Bayer AG
  • Vifor Pharma Management Ltd.
  • Akebia Therapeutics, Inc.

第14章 附錄

目錄
Product Code: TIPRE00013768

Title:
Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography.

The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020-2027.

The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage, the kidney loses its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life.

At present, there is no cure for chronic kidney disease, and treatment involves the managing of the disease. Blood pressure medications, such as angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, are frequently prescribed to control hypertension, and expectantly, to slowdown the progression of chronic kidney disease. Therefore, the manufacturers in the market are focusing on adopting strategies such as product launches and approvals, R&D investments, government funding, and partnerships to develop new drugs and provide easy access for the patients worldwide.

Some of the manufactures are mentioned below:

DiaMedica Drugs

On February 14, 2019 DiaMedica Drugs Inc, a clinical-stage biotechnology company, announced that it has initiated dosing patients with chronic kidney disease in a Phase Ib clinical study evaluating DM199. The course is conducted in the U.S., is a multi-center, open-label clinical trial to assess the tolerability, safety, and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. This study will help determine the dose levels required to restore normal KLK1 protein levels in patients with CKD and provide extra insights about the specific CKD patient populations that may benefit most from DM199 treatment and guide the upcoming design Phase II studies.

Cara Drugs, Inc.

Cara Drugs, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to improve pruritus and pain by selectively targeting peripheral kappa opioid receptors, on July 2017 announced that it had dosed the first patient in its Phase 1 pharmacokinetic and safety trial of Oral CR845 tablets in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis.

Akebia Drugs

Akebia Drugs, Inc., a biopharmaceutical company engaged in the development of the with the purpose to better the lives of people impacted by kidney disease, on June 2020 announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD). Moreover, Mitsubishi Tanabe Pharma Corporation, Akebia's collaboration partner in Japan for vadadustat, has received manufacturing and marketing approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour, and Welfare in Japan. Mitsubishi Tanabe Pharma Corporation will market Vadadustat in Japan under the trade name VAFSEO.

Based on product type, the market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.

Based on indication, the global late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. The late stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), European Federation of Pharmaceutical Industry Associations, Pharmaceutical Research, National Kidney Foundation, and Organization for Economic Cooperation and Development are among the major primary and secondary sources referred for preparing this report.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the late stage chronic kidney disease drugs market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global late stage chronic kidney disease drugs market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Late Stage Chronic Kidney Disease Drugs Market - By Product Type
    • 1.3.2 Late Stage Chronic Kidney Disease Drugs Market - By Indication
    • 1.3.3 Late Stage Chronic Kidney Disease Drugs Market - By Distribution Channel
    • 1.3.4 Late Stage Chronic Kidney Disease Drugs Market - By Geography

2. Late Stage Chronic Kidney Disease Drugs Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Late Stage Chronic Kidney Disease Drugs Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America - PEST Analysis
    • 4.2.2 Europe - PEST Analysis
    • 4.2.3 Asia-Pacific - PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) - PEST Analysis
    • 4.2.5 South & Central America (SCAM) - PEST Analysis
  • 4.3 Expert Opinion

5. Late Stage Chronic Kidney Disease Drugs Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases
    • 5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs
  • 5.2 Market Restraints
    • 5.2.1 Delay in the Diagnosis of Chronic Kidney Disease
  • 5.3 Market Opportunities
    • 5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
  • 5.4 Future Trends
    • 5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
  • 5.5 Impact Analysis

6. Late Stage Chronic Kidney Disease Drugs Market - Global Analysis

  • 6.1 Global Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast And Analysis
  • 6.2 Global Late Stage Chronic Kidney Disease Drugs Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Late Stage Chronic Kidney Disease Drugs Market Analysis - By Product Type

  • 7.1 Overview
  • 7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
  • 7.3 Calcimimetics
    • 7.3.1 Overview
    • 7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.4 Vitamin D
    • 7.4.1 Overview
    • 7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.5 Potassium Binders
    • 7.5.1 Overview
    • 7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.6 Calcium-Based Phosphate Binders
    • 7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.7 Others
    • 7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

8. Late Stage Chronic Kidney Disease Drugs Market Analysis By Indication

  • 8.1 Overview
  • 8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
  • 8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
    • 8.3.1 Overview
    • 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
    • 8.4.1 Overview
    • 8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia
    • 8.5.1 Overview
    • 8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

9. Late Stage Chronic Kidney Disease Drugs Market Analysis By Distribution Channel

  • 9.1 Overview
  • 9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)
  • 9.3 Hospital Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.4 Online Pharmacies
    • 9.4.1 Overview
    • 9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.5 Retail Pharmacies
    • 9.5.1 Overview
    • 9.5.2 Retail Pharmacies Segment : Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

10. Late Stage Chronic Kidney Disease Drugs Market Analysis And Forecasts To 2027 - Geographical Analysis

  • 10.1 North America: Late Stage Chronic Kidney Disease Drugs Market
    • 10.1.1 Overview
    • 10.1.2 North America: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.1.3 North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.1.4 North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.1.5 North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.6 North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.1.7 US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.1 US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.2 US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.3 US: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.4 US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.8 Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.1 Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.2 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.3 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.4 Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.9 Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.1 Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.2 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.3 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.4 Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.2 Europe: Late Stage Chronic Kidney Disease Drugs Market
    • 10.2.1 Overview
    • 10.2.2 Europe: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.2.3 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.2.4 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.2.5 Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.6 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.2.7 Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.1 Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.2 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.3 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.4 Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.8 France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.1 France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.2 France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.3 France: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.4 France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.9 UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.1 UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.2 UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.3 UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.4 UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.10 Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.1 Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.2 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.3 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.4 Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.11 Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.1 Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.2 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.3 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.4 Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.3 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market
    • 10.3.1 Overview
    • 10.3.2 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.3.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.3.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.3.5 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.3.6 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.4.1 China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.1 China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.2 China Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.3 China Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.4 China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.2 Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.1 Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.2 Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.3 Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.4 Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.3 India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.1 India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.2 India Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.3 India Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.4 India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.4 South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.1 South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.2 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.3 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.4 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.5 Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.1 Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.2 Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.3 Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.4 Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.5 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market
    • 10.5.1 Overview
    • 10.5.2 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
    • 10.5.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
    • 10.5.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
    • 10.5.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.6 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)
    • 10.5.7 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.1 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.2 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.3 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.4 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.8 UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.1 UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.2 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.3 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.4 UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.9 South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.1 South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.2 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.3 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.4 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • 10.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market
    • 10.6.1 Overview
    • 10.6.2 South and Central America: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.6.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.6.4 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.6.5 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.6.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.6.7 Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.1 Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.2 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.3 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.4 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.6.8 Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.1 Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.2 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.3 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.4 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)

11. Impact of COVID-19 Pandemic on Global Late Stage Chronic Kidney Disease Drugs Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Late Stage Chronic Kidney Disease Drugs Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 AbbVie Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Amgen
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 AstraZeneca
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Sanofi
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Kyowa Kirin Co., Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Takeda Pharmaceutical Company Limited
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Astellas Pharma Inc.
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bayer AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Vifor Pharma Management Ltd.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Akebia Therapeutics, Inc.
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 Glossary of Terms

List Of Tables

  • Table 1. North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 2. North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 3. North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 4. US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 5. US: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 6. US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 7. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 8. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 9. Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 10. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 11. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 12. Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 13. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 14. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 15. Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 16. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 17. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 18. Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 19. France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 20. France: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 21. France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 22. UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 23. UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 24. UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 25. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 26. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 27. Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 28. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 29. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 30. Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 31. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 32. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 33. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 34. China Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 35. China Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 36. China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 37. Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 38. Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 39. Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 40. India Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 41. India Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 42. India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 43. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 44. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 45. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 46. Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 47. Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 48. Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 49. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
  • Table 50. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
  • Table 51. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 52. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 53. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 54. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 55. UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
  • Table 56. UAE Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 57. UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 58. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 59. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 60. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel- Revenue and Forecast to 2027(USD Million)
  • Table 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 62. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 63. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel- Revenue and Forecast to 2027(USD Million)
  • Table 64. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 65. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 66. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 67. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 68. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 69. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 70. Organic Developments Done By Companies
  • Table 71. Inorganic Developments Done by Companies
  • Table 72. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market

List Of Figures

  • Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation
  • Figure 2. Late Stage Chronic Kidney Disease Drugs Market - By Geography
  • Figure 3. Global Late Stage Chronic Kidney Disease Drugs Market Overview
  • Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market
  • Figure 5. Asia-Pacific to Show Remarkable Growth During Forecast Period
  • Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market, By Geography (US$ Million)
  • Figure 7. Global Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)
  • Figure 8. Global Late Stage Chronic Kidney Disease Drugs Market, Industry Landscape
  • Figure 9. North America PEST Analysis
  • Figure 10. Europe PEST Analysis
  • Figure 11. Asia-Pacific PEST Analysis
  • Figure 12. Middle East and Africa (MEA) PEST Analysis
  • Figure 13. South & Central America (SCAM) PEST Analysis
  • Figure 14. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints
  • Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market - Revenue Forecast And Analysis - 2019- 2027
  • Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market - By Geography Forecast and Analysis - 2019- 2027
  • Figure 17. Market Positioning of Key Players
  • Figure 18. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
  • Figure 19. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 20. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 21. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 22. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 23. Others: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 24. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
  • Figure 25. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 26. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 27. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 28. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
  • Figure 29. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 30. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 31. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 32. North America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 33. North America: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 34. North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 35. US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 36. Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 37. Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 38. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 39. Europe: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 40. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 41. Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 42. France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 43. UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 44. Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 45. Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 46. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 47. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 48. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 49. China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 50. Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 51. India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 52. South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 53. Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 54. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 55. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 56. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)
  • Figure 57. Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 58. UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 59. South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 60. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 62. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 63. Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 64. Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 65. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In North American Countries
  • Figure 66. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In European Countries
  • Figure 67. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In Asia Pacific Countries
  • Figure 68. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in Rest of the World
  • Figure 69. Growth Strategies Done by the Companies in the Market, (%)